Innovations in Product Design and Materials Brighten Outlook for Non-Vascular Stents Market
Changing lifestyles have led to a rise in gastrointestinal diseases, urological problems, glaucoma and other conditions, which necessitate the use of non-vascular stents. The increase in gastro-urological and respiratory morbidities, in particular, demands the use of non-vascular stents as they can help maintain vessel patency. With the accelerating demand for minimally invasive treatments, which cause less pain, enable faster recovery, and involve shorter hospital stays, the non-vascular stent market is likely to witness encouraging growth trends.
New analysis from Frost & Sullivan, Technology Innovations in Non-Vascular Stents, finds that innovations in biodegradable and other materials, unique technological properties of metals and polymers like the capacity to self-expand, and advanced deployment techniques will fuel advances in the non-vascular stents sector.
“Material and technology innovations have enabled the development of specially designed stents that can be used for versatile indications,” noted Technical Insights Industry Analyst Debarati Sengupta. “This has increased the diversity of non-vascular stents applications, the size of the target patient pool, and the confidence among physicians using these products.”
Key concerns for physicians include complications surrounding stent migration due to forces experienced at the sites of implantation and problems associated with stent removal. The lack of evidence regarding the overall safety of newer designs and materials used to develop non-vascular stents will also restrain market development.
As such, the sustained publication of clinical safety information will go a long way in convincing physicians and patients of the safety of non-vascular stents. Physicians and patients must be aware of the latest product developments; for instance, the upcoming introduction of micro-stents in the neural and ophthalmic application segments. Along with this, market participants should efficiently train physicians and surgeons on the way to carry out procedures that require non-vascular stents to boost adoption rates.
The premium price tag that non-vascular stents come with will continue to suppress uptake in the short term. However, technological innovations and material improvements are likely to lower the cost of non-vascular stents in the medium- and long-term.
“Other major issues surrounding the ease of deployment will also lose relevance as advances in non-vascular stents through proprietary technologies gain pace,” concluded Sengupta. “Ultimately, this will result in the enhanced usage of these products in interventional procedures as well.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance